Jazz Pharmaceuticals plc
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
JAZZ$245.43+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets – March, 202 and December 31,
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31,2026 | December 31,2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,844.3 | $1,391.9 |
| Investments | 1,030.0 | 1,050.0 |
| Accounts receivable, net of allowances | 836.3 | 830.7 |
| Inventories | 437.5 | 417.0 |
| Prepaid expenses | 149.7 | 152.5 |
| Other current assets | 285.3 | 323.9 |
| Total current assets | 4,583.1 | 4,166.0 |
| Property, plant and equipment, net | 203.1 | 199.9 |
| Operating lease assets | 55.8 | 58.9 |
| Intangible assets, net | 4,203.8 | 4,429.5 |
| Goodwill | 1,805.0 | 1,829.3 |
| Deferred tax assets, net | 907.0 | 869.1 |
| Deferred financing costs | 7.1 | 7.6 |
| Other non-current assets | 94.7 | 99.0 |
| Total assets | $11,859.6 | $11,659.3 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $100.0 | $122.1 |
| Accrued liabilities | 1,022.4 | 1,034.2 |
| Current portion of long-term debt | 1,030.5 | 1,029.9 |
| Income taxes payable | 93.7 | 56.3 |
| Total current liabilities | 2,246.6 | 2,242.5 |
| Long-term debt, less current portion | 4,324.2 | 4,328.4 |
| Operating lease liabilities, less current portion | 47.3 | 50.9 |
| Deferred tax liabilities, net | 547.7 | 594.5 |
| Other non-current liabilities | 161.5 | 124.4 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity: | ||
| Ordinary shares | — | — |
| Non-voting euro deferred shares | 0.1 | 0.1 |
| Capital redemption reserve | 0.5 | 0.5 |
| Additional paid-in capital | 4,243.5 | 4,240.5 |
| Accumulated other comprehensive loss | (651.0) | (568.6) |
| Retained earnings | 939.2 | 646.1 |
| Total shareholders’ equity | 4,532.3 | 4,318.6 |
| Total liabilities and shareholders’ equity | $11,859.6 | $11,659.3 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.